111 related articles for article (PubMed ID: 22285569)
1. Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA).
Venkatraj M; Messagie J; Joossens J; Lambeir AM; Haemers A; Van der Veken P; Augustyns K
Bioorg Med Chem; 2012 Feb; 20(4):1557-68. PubMed ID: 22285569
[TBL] [Abstract][Full Text] [Related]
2. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
[TBL] [Abstract][Full Text] [Related]
3. 3-Amidinophenylalanine-based inhibitors of urokinase.
Stürzebecher J; Vieweg H; Steinmetzer T; Schweinitz A; Stubbs MT; Renatus M; Wikström P
Bioorg Med Chem Lett; 1999 Nov; 9(21):3147-52. PubMed ID: 10560742
[TBL] [Abstract][Full Text] [Related]
4. Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines.
Fish PV; Barber CG; Brown DG; Butt R; Collis MG; Dickinson RP; Henry BT; Horne VA; Huggins JP; King E; O'Gara M; McCleverty D; McIntosh F; Phillips C; Webster R
J Med Chem; 2007 May; 50(10):2341-51. PubMed ID: 17447747
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.
Wendt MD; Rockway TW; Geyer A; McClellan W; Weitzberg M; Zhao X; Mantei R; Nienaber VL; Stewart K; Klinghofer V; Giranda VL
J Med Chem; 2004 Jan; 47(2):303-24. PubMed ID: 14711304
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
7. Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.
Bruncko M; McClellan WJ; Wendt MD; Sauer DR; Geyer A; Dalton CR; Kaminski MA; Weitzberg M; Gong J; Dellaria JF; Mantei R; Zhao X; Nienaber VL; Stewart K; Klinghofer V; Bouska J; Rockway TW; Giranda VL
Bioorg Med Chem Lett; 2005 Jan; 15(1):93-8. PubMed ID: 15582418
[TBL] [Abstract][Full Text] [Related]
8. Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
Barbault F; Maurel F
J Comput Chem; 2012 Mar; 33(6):607-16. PubMed ID: 22241532
[TBL] [Abstract][Full Text] [Related]
9. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
10. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
De Souza M; Matthews H; Lee JA; Ranson M; Kelso MJ
Bioorg Med Chem; 2011 Apr; 19(8):2549-56. PubMed ID: 21454081
[TBL] [Abstract][Full Text] [Related]
11. Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.
Wendt MD; Geyer A; McClellan WJ; Rockway TW; Weitzberg M; Zhao X; Mantei R; Stewart K; Nienaber V; Klinghofer V; Giranda VL
Bioorg Med Chem Lett; 2004 Jun; 14(12):3063-8. PubMed ID: 15149645
[TBL] [Abstract][Full Text] [Related]
12. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
Matthews H; Ranson M; Tyndall JD; Kelso MJ
Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators.
Pettersson M; Johnson DS; Subramanyam C; Bales KR; am Ende CW; Fish BA; Green ME; Kauffman GW; Lira R; Mullins PB; Navaratnam T; Sakya SM; Stiff CM; Tran TP; Vetelino BC; Xie L; Zhang L; Pustilnik LR; Wood KM; O'Donnell CJ
Bioorg Med Chem Lett; 2012 Apr; 22(8):2906-11. PubMed ID: 22429469
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and activity of amides of tripeptides as potential urokinase inhibitors.
Markowska A; Bruzgo I; Midura-Nowaczek K
J Enzyme Inhib Med Chem; 2010 Feb; 25(1):139-42. PubMed ID: 20030517
[TBL] [Abstract][Full Text] [Related]
17. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Frederickson M; Callaghan O; Chessari G; Congreve M; Cowan SR; Matthews JE; McMenamin R; Smith DM; Vinković M; Wallis NG
J Med Chem; 2008 Jan; 51(2):183-6. PubMed ID: 18163548
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.
Andrews HN; Habibi G; Kucab JE; Dunn SE
Breast Cancer Res Treat; 2005 Nov; 94(1):47-52. PubMed ID: 16172791
[TBL] [Abstract][Full Text] [Related]
19. Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
Liang OD; Chavakis T; Linder M; Bdeir K; Kuo A; Preissner KT
Biol Chem; 2003 Feb; 384(2):229-36. PubMed ID: 12675515
[TBL] [Abstract][Full Text] [Related]
20. Synthetic urokinase inhibitors as potential antitumor drugs.
Steinmetzer T
IDrugs; 2003 Feb; 6(2):138-46. PubMed ID: 12789617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]